Kodiak Sciences shares rose 177.96% after Phase 3 eye-drug results

Kodiak Sciences shares closed at $89.92 on September 28, 2026, up 177.96% from $32.35 on September 25, after the company announced positive Phase 3 results for two experimental eye drugs before the market opened. KOD reached an intraday high of $95.77, and 38,225,697 shares traded during the session, compared with 2,171,434 on September 25, according to historical price data. The trial announcement is the supported explanation for the move. The closing price cannot show how investors valued each drug separately.

What DAYBREAK established

At 6:30 a.m. EDT, Kodiak reported that Zenkuda, also called tarcocimab tedromer, and tabirafusp-ted, also called KSI-501, each met the DAYBREAK trial’s one-year primary endpoint in previously untreated wet age-related macular degeneration. Both produced vision gains that met the trial’s standard for non-inferiority to aflibercept, which Regeneron markets as Eylea. Kodiak reported non-inferiority p-values of 0.0007 for Zenkuda and 0.0036 for tabirafusp-ted. The findings establish that both drugs met the specified comparison; they do not establish superior vision gains.

Kodiak also reported that 54% of Zenkuda-treated participants reached a 24-week dosing interval at one year under the trial’s retinal-fluid-based retreatment rules. A longer interval could reduce the number of treatments for some patients. That figure describes outcomes under DAYBREAK’s protocol and in its treatment-naïve population. Fuller injection-frequency data and experience beyond the trial will be needed to assess how broadly the interval applies.

The company reported intraocular inflammation rates of 0% for Zenkuda and 0.4% for tabirafusp-ted. Reported cataract adverse-event rates were 0.5% for Zenkuda, 0% for tabirafusp-ted and 0.9% for aflibercept. These are company-reported trial results. Their relevance is heightened by Zenkuda’s history: the drug previously failed to match Eylea in a wet-AMD trial, and Kodiak temporarily stopped its development in 2023 after an increase in cataracts.

What the results mean for Kodiak

Meeting both prespecified vision endpoints removes a major clinical obstacle to Kodiak’s planned filing for Zenkuda and supplies late-stage evidence for tabirafusp-ted. Kodiak plans to submit a biologics license application for Zenkuda in the fourth quarter of 2026, covering wet AMD, diabetic retinopathy and retinal-vein-occlusion-related macular edema using five Phase 3 studies. The filing remains a company plan; the FDA has not accepted or approved the application.

DAYBREAK leaves important commercial comparisons open. Its comparator was conventional aflibercept dosing. The trial did not directly compare Zenkuda with Eylea HD, Roche’s Vabysmo or lower-cost aflibercept biosimilars. The reported 24-week interval gives Kodiak a potential treatment-burden distinction, while the topline results cannot establish demand or an advantage over those alternatives. Kodiak’s descriptions of Zenkuda as a potential new standard of care or best-in-class therapy remain company assessments.

The tabirafusp-ted result also has a defined limit. Its non-inferiority result against aflibercept does not demonstrate an added clinical benefit from inhibiting IL-6. Kodiak says it will conduct post-hoc subgroup analyses and is separately testing superiority to aflibercept in the Phase 3 ALTO diabetic-macular-edema study. ALTO’s outcome remains unknown.

Kodiak is precommercial, making the route from trial results to a marketed product financially consequential. In its August 13 results, the company reported $125.9 million in cash at June 30 and a second-quarter net loss of $65.6 million. It expected existing cash to support operations into 2027. That estimate depends on spending and financing assumptions; approval, manufacturing readiness and reimbursement remain unresolved.

Other stocks and next milestones

Regeneron closed September 28 down 4.54% at $752.25, while Ocular Therapeutix fell 20.67% to $7.66. Those concurrent moves do not establish a single cause for either decline. Reuters reported Ocular’s fall as Kodiak’s results arrived, while RBC Capital Markets analyst Lisa Walter called Ocular’s selloff overdone and argued its long-acting candidate AXPAXLI remained well positioned. Her assessment is an analyst judgment, and DAYBREAK did not test AXPAXLI.

The next checks on the September 28 reaction are Kodiak’s planned fourth-quarter Zenkuda filing, the application’s proposed data and dosing claims, and any subsequent FDA decisions. Fuller DAYBREAK efficacy, injection-frequency and safety analyses will help clarify what the topline results support. Kodiak also expects a December 2026 Phase 3 PEAK readout for its separate candidate KSI-101.

MacroShed Markets is informational analysis, not investment advice.